In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alex Shimmings

Executive Editor, Europe Commercial

London, UK
Alex has held a variety of editorial positions of increasing seniority on Scrip since joining the publication as a science reporter in 1998. Currently, she heads up the European editorial team coverage of commercial and R&D developments, while also writing news, analysis and features. Over the years, Alex has covered breakthroughs in R&D in a range of therapeutic areas, including infectious diseases, cardiology and cancer, and she enjoys interviewing key industry players and opinion leaders. Alex has a degree in Biochemistry and Microbiology from the University of Leeds and a keen interest in medical history.

Latest From Alex Shimmings

Nine Pivotal Studies To Look Out For In 2024

While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.

Clinical Trials Commercial

10 Pivotal Studies To Look Out For In 2024

While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.

Scrip Perspectives Clinical Trials

Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors

The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow.

Companies Cancer

Five Clinical Trial Misses Of 2023

The biopharma industry’s fate lies largely in its R&D success and failures. Here, Scrip looks at five clinical trial failures that got readers clicking in 2023. Some were more comprehensive than others, highlighting the nuance that can be injected into clinical data in different settings and subgroups.

Scrip Perspectives Clinical Trials

Five Clinical Trial Hits Of 2023

The biopharma industry’s fate lies largely in its R&D successes and failures. Here, Scrip looks at five clinical trial successes that will shape their sponsors’ futures and got readers clicking in 2023.

Scrip Perspectives Clinical Trials

Olema Boosts Its Partnering Position With SERD Combo Data

Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.

Clinical Trials Companies
See All
UsernamePublicRestriction

Register